16.03.2023 • News

Apollo Takes Univar for $8.1 Billion

Private equity group Apollo has agreed to acquire Univar Solutions for $8.1 billion. The transaction also includes a “minority” investment from a wholly owned subsidiary of the Abu Dhabi Investment Authority.

© Shutterstock/AVAVA
© Shutterstock/AVAVA

"We are pleased to have reached this agreement with Apollo, which will provide immediate and certain cash value for Univar Solutions shareholders," said Univar chairman Chris Pappas. "The board's decision follows a comprehensive review of value creation opportunities for Univar Solutions. We are confident this transaction is the right path forward and achieves our goal of maximizing value for Univar Solutions shareholders."

Apollo partner Sam Feinstein added that Univar can accelerate its long-term strategy as one of its portfolio companies.

The transaction is expected to close in the second half of 2023, subject to customary conditions and including approval by Univar Solutions shareholders. Once the deal is finalized, Univar will become a private company and no longer trade on the New York Stock Exchange. It will, however, continue to operate under the Univar Solutions name and brand.

Activist investor Engine Capital has been urging Univar to consider a sale or other options, saying the distributor was deeply undervalued and had been unable to generate adequate returns for investors. Late last year, the US distributor and German distribution giant Brenntag started preliminary talks but the companies announced in January that these had ended.

Author: Elaine Burridge, Freelance Journalist

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.